Evidence map›Paper›PMID 37869260›Full record

ArticleMolecular therapy. Nucleic acids2023

A DNA/RNA heteroduplex oligonucleotide coupling asparagine depletion restricts FGFR2 fusion-driven intrahepatic cholangiocarcinoma.

Zhenzhen Chu, Baohuan Zhang, Xuxuan Zhou, Hui Yuan, Chongqing Gao, Lihao Liu, Yang Xiao, Jichun Zhang, Jian Hong, Junjie Liang and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. METTL1-mediated mOncogene · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Zhenzhen ChuDepartment of Pathophysiology, School of Medicine, Jinan University, Guangzhou, Guangdong 510632, China.
Baohuan ZhangMorphology Experimental Teaching Center, School of Medicine, Jinan University, Guangzhou, Guangdong 510632, China.
Xuxuan ZhouDepartment of Pathophysiology, School of Medicine, Jinan University, Guangzhou, Guangdong 510632, China.
Hui YuanDepartment of Gastroenterology, Huizhou Municipal Central Hospital, Huizhou, Guangdong 516001, China.
Chongqing GaoDepartment of Pathophysiology, School of Medicine, Jinan University, Guangzhou, Guangdong 510632, China.
Lihao LiuSchool of Medicine, Jinan University, Guangzhou, Guangdong 510632, China.
Yang XiaoDepartment of Hepatobiliary Surgery, the First Affiliated Hospital, Jinan University, Guangzhou, Guangdong 510632, China.
Jichun ZhangDepartment of Physiology, School of Medicine, Jinan University, Guangzhou, Guangdong 510632, China.
Jian HongDepartment of Pathophysiology, School of Medicine, Jinan University, Guangzhou, Guangdong 510632, China.
Junjie LiangDepartment of Hepatobiliary Surgery, the First Affiliated Hospital, Jinan University, Guangzhou, Guangdong 510632, China.
Dong ChenDepartment of Pancreato-Biliary Surgery, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510080, China.
Nan YaoDepartment of Pathophysiology, School of Medicine, Jinan University, Guangzhou, Guangdong 510632, China.
Jinan University · CNFirst Affiliated Hospital of Jinan University · CNHuizhou Central People's Hospital · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pemigatinib, a pan-FGFR inhibitor, is approved to treat intrahepatic cholangiocarcinoma (ICC) harboring FGFR2 fusion mutations. Improving its targeting of FGFR2 fusions remains an unmet clinical need due to its pan selectivity and resistance. Here, we report a cholesterol-conjugated DNA/RNA heteroduplex oligonucleotide targeting the chimeric site in

Indexed as

combination therapyFGFR2 fusion mutationsintrahepatic cholangiocarcinomaMT: Oligonucleotides: Therapies and Applicationsnucleic acid drugstargeted therapy

Identifiers

PMID37869260
PMCPMC10589379
OpenAlexW4387372570

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.